Johnson & Johnson completes $17bn acquisition of Abiomed
Johnson & Johnson (J&J) has closed the previously announced acquisition of Abiomed, a medical device technology company, for an enterprise value of around $16.6bn, in ... Read More
Abiomed gets FDA nod for Impella ECP pivotal heart pump in clinical trial
The US Food and Drug Administration (FDA) has cleared Abiomed to use the company’s version of Impella ECP pivotal heart pump in pivotal clinical trial. ... Read More
Johnson & Johnson to purchase heart pump maker Abiomed for $16.6bn
Johnson & Johnson (J&J) has agreed to acquire Abiomed, a NASDAQ-listed cardiovascular medical technology provider, in an all-cash deal valued at approximately $16.6 billion. The ... Read More